Aptar and Healint announce collaboration on CNS and immune system conditions management

pharmafile | April 24, 2023 | News story | Medical Communications  

AI healthcare company Healint and Software as a Medical Device (SaMD) expert Aptar Digital Health have announced a collaboration aiming to improve central nervous system (CNS) and immune system conditions management.


Healint will bring its AI technology ‒ which includes innovations in software, data science and user experience design ‒ to collect, analyse and interpret large quantities of patient-generated data. Aptar will offer experience in SaMD, companion apps and disease management solutions, its expertise in developing and implementing digital health solutions complementing Healint’s AI-driven insights.


This partnership aims to develop a new category of patient support programmes (PSPs), digital therapeutics (DTx) and studies. The companies will showcase their capacity to produce high precision real-world algorithms for treatment evaluation, and predictive analytics to optimise the timing of treatment intake.


François Cadiou, CEO and co-founder of Healint commented: “At Healint, we are delighted by our collaboration with Aptar Digital Health as we know together we will be able to deliver the best to our clients. We are combining Aptar’s proven experience with digital patient support coupled with Healint’s ten years of building the world leading platform for CNS. Our clients know we are the best option to bring their digital projects to life and surpass the competition’s digital initiative. This will open new treatment and relief opportunities in migraine as well as numerous other chronic conditions.”


Adam Shain, vice president of Business Development at Aptar Digital Health, stated: “We are excited to join forces with Healint and bring our combined expertise to address the significant challenges faced by patients with CNS and immune system conditions. Our collaboration represents a major step forward in our shared mission to improve the lives of millions of people worldwide.”


James Spargo

Related Content

No items found

Latest content